Drug-tolerant persister (DTP) cell populations were originally discovered in antibiotic-
resistant bacterial biofilms. Similar populations with comparable features have since been …

We report a personalized tumor-informed technology, Patient-specific pROgnostic and
Potential tHErapeutic marker Tracking (PROPHET) using deep sequencing of 50 patient …

High-grade serous ovarian cancer (HGSC) is frequently characterized by homologous
recombination (HR) DNA repair deficiency and, while most such tumors are sensitive to …

Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden
and provide unique insights into the evolving molecular landscape of cancers under the …

Introduction Colorectal cancer is the fourth most common cancer in the UK. There remains a
need for improved risk stratification following curative resection. Circulating-tumour DNA …

Tissue-based biopsy is the present main tool to explore the molecular landscape of cancer,
but it also has many limits to be frequently executed, being too invasive with the risk of side …

Gastric adenocarcinoma, even when diagnosed at an early (localized) disease stage, poses
a major health-care burden with cure rates that remain unsatisfactorily low, particularly in …

The last decade has seen rapid progress in the use of genomic tests, including gene panels,
whole‐exome sequencing, and whole‐genome sequencing, in research and clinical cancer …

In the era of precision oncology, use of circulating tumor DNA (ctDNA) is emerging as a
minimally invasive approach for the diagnosis and management of patients with cancer and …

Precision cancer medicine is a multidisciplinary team effort that requires involvement and
commitment of many stakeholders including the society at large. Building on the success of …